Premium
Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Author(s) -
Spekhorst Lotte S.,
Bakker Daphne,
Drylewicz Julia,
Rispens Theo,
Loeff Floris,
Boesjes Celeste M.,
Thijs Judith,
Romeijn Geertruida L. E.,
Loman Laura,
Schuttelaar MarieLouise,
Wijk Femke,
Graaf Marlies,
BruinWeller Marjolein S.
Publication year - 2022
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.15439
Subject(s) - dupilumab , medicine , dosing , atopic dermatitis , regimen , eczema area and severity index , scorad , gastroenterology , interquartile range , dermatology life quality index , dermatology , disease
Background At present, no real‐world studies are available on different dupilumab dosing regimens in controlled atopic dermatitis (AD). The aim of this study was to clinically evaluate a patient‐centered dupilumab dosing regimen in patients with controlled AD and to relate this to serum drug levels and serum biomarkers. Methods Ninety adult AD patients from the prospective BioDay registry were included based on their dupilumab administration interval according to a predefined patient‐centered dosing regimen. Group A ( n = 30) did not fulfill the criteria for interval prolongation and continued using the standard dupilumab dosage (300 mg/2 weeks), group B ( n = 30) prolonged dupilumab interval with 50% (300 mg/4 weeks), and group C ( n = 30) prolonged dupilumab interval with 66%–75% (300 mg/6–8 weeks). AD severity score, patient‐reported outcomes, serum dupilumab levels, and serum biomarkers were analyzed over time. Results Disease severity scores did not significantly change over time during the tapering period in any of the groups. In groups B and C, the Numeric Rating Scale (NRS)‐pruritus temporarily significantly increased after interval prolongation but remained low (median NRS‐pruritus≤4). Median dupilumab levels remained stable in group A (standard dosage), but significantly decreased in groups B and C (24.1 mg/L (IQR = 17.1–45.6); 12.5 mg/L (IQR = 1.7–22.3)) compared with the levels during the standard dosage (88.2 mg/L [IQR = 67.1–123.0, p < .001]). Disease severity biomarker levels (CCL17/CCL18) remained low in all study groups during the whole observation period. Conclusions This study showed that dose reduction was successful in a subgroup of patients with controlled AD by using a patient‐centered dosing regimen. These patients showed stable low disease activity and low severity biomarkers over time.